Výsledky vyhledávání

Akademický článek

Continuous Low-Dose Apatinib Combined With WBRT Significantly Reduces Peritumoral Edema and Enhances the Efficacy of Symptomatic Multiple Brain Metastases in NSCLC

Autor: Yue Ren MSc, Shan-Bing Wang MSc, Lin Zhou PhD, Si-Qiao Liu MSc, Lei-Ya Du MSc, Ting Li MSc, Mao-Qiong Jiang BSc, Kai-Jian Lei MSc, Bang-Xian Tan MSc, Yu-Ming Jia BSc

Publikováno v: Technology in Cancer Research & Treatment, Vol 20 (2021)

Background: Symptomatic multiple brain metastases with peritumoral brain edema (PTBE) occur in non-small cell lung cancer patients (NSCLC) who are without driver mutations or are resistant to epidermal growth factor tyrosine kinase (EGFR-TKI) are oft

Externí odkaz: https://doaj.org/article/a818e40f26e14d65a872be7b03ec7023

Zobrazit plný text záznamu

Continuous Low-Dose Apatinib Combined With WBRT Significantly Reduces Peritumoral Edema and Enhances the Efficacy of Symptomatic Multiple Brain Metastases in NSCLC

Autor: Shan-Bing Wang, Yu-Ming Jia, Yue Ren, Mao-Qiong Jiang, Lin Zhou, Lei-Ya Du, Ting Li, Kai-Jian Lei, Bangxian Tan, Si-Qiao Liu

Publikováno v: Technology in Cancer Research & Treatment
Technology in Cancer Research & Treatment, Vol 20 (2021)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::165c77c686e80e958ab2cd7bae067ef8
https://pubmed.ncbi.nlm.nih.gov/33955301

Zobrazit plný text záznamu

Apatinib‐induced Grade 3 hand‐foot syndrome in advanced lung adenocarcinoma successful treated with thalidomide: A case report

Autor: Yu-Ming Jia, Ting Li, Yue Ren, Kai-Jian Lei, Ye Qiu, Shan-Bing Wang, Lei-Ya Du

Publikováno v: Dermatologic Therapy. 33

Hand-foot syndrome (HFS) is a specific cutaneous toxicity caused by a variety of antitumor drugs. The most common drugs include capecitabine, pegylated liposomal doxorubicin and fluorouracil (PLD), tyrosine kinase inhibitor. It is a dose-limiting cut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aabebd882a88ca4e6861e579103048a
https://doi.org/10.1111/dth.13241

Zobrazit plný text záznamu

The very early tumor regression rate and safety of anlotinib combined with sintilimab and chemotherapy for advanced non-small cell lung cancer without driver mutations

Autor: Mao-Qiong Jiang, Lei-Ya Du, Ting Li, Jian Jiang, Li Li, Jie Chen, Yu-Ming Jia, Jun Yan, Ye Qiu, Yue Ren

Publikováno v: Journal of Clinical Oncology. 39:e21090-e21090

e21090 Background: Unlike bevacizumab, anlotinib, which is also an anti-angiogenic drug, is indicated for lung squamous cell carcinoma(LSCC). A phase IB study showed that the first-line therapy with anlotinib and sintilimab for stage IIIB to IV NSCLC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cc89cb8f87577a8e1beb1249b6ff575b
https://doi.org/10.1200/jco.2021.39.15_suppl.e21090

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání